The Short Oral Contribution Award was delivered to Dr. Satu Pekkala

During the Targeting Microbiota 2019 congress, which was held in Krakow, Poland, the Scientific Committee awarded Dr. Satu Pekkala, from University of Jyvaskyla, Finland, for her Oral Presentation entitled "Targeting Faecalibacterium prausnitzii with prebiotic xylo oligosaccharides prevents from Non-Alcoholic Fatty Liver Disease (NAFLD)"

The study presented by Dr. Pekkala identifies F. prausnitzii as target treat NAFLD and the underlying preventive mechanisms that involve fat oxidation and glucose metabolism. 

Testimonial by Dr. Pekkala: 
" I am very honored for this award and I congratulate the International of Society of Microbiota by organizing the congress 7th Targeting Microbiota full of excellent presentations. I have always thought that the gut microbiota studies should advance from detecting associations to show mechanistically the biological significance of the detected associations. This is needed to be able to target the microbes to treat different diseases in the future. Therefore, I am thrilled to see the development of the gut microbiota studies from year to year in this congress!

I am currently Academy of Finland Research Fellow at the Faculty of Sport and Health Sciences, University of Jyväskylä, Finland. I am also Adjunct Professor at the Faculty of Medicine, University of Turku, Finland. My research team has discovered that a specific gut bacterium, Faecalibacterium prausnitzii associated with liver fat content in humans. We treated a murine model of fatty liver with this bacterium and found that it was able to prevent the disease. Unfortunately, the potential therapeutic microbes are not always accepted for human use and therefore it is important to find alternative ways to increase their natural abundance in the gut. As I presented in the congress, we found a prebiotic fibre that increased F. prausnitzii in vivo and at the same could prevent fatty liver in rats. We are currently setting up a human study to see whether our findings can be translated to humans."

Media center:
International Society of Microbiota
Contact: [email protected]
www.microbiota-site.com

Prof. Chantal Pichon, French National Centre for Scientific Research, France, awarded by International Society of Microbiota

International Society of Microbiota (ISM) is honored to announce the winner of the Scientific Contribution Award for the year 2019, Prof. Chantal Pichon from French National Centre for Scientific Research, University of Orléans, France.

Prof. Chantal Pichon gave an excellent communication during the 7th World Congress on Targeting Microbiota 2019, which was held in Krakow, Poland, on the Dialogue between the skin and the microbiota: The immune system is under control. 

Testimonial of Prof. Pichon:
"I am indebted to the organizers for inviting me to speak at Targeting Microbiota and giving me the award. It was an inspiring and very high level conference. Cutting Edge research projects have been presented indicating how fast is growing the knowledge in the field and how we could together tackle the challenges on developing novel therapies based on microbiota interaction with our body."

Oral presentation of Prof. Chantal Pichon during Targeting Microbiota 2019:
The skin, the largest organ of our body is also the outermost barrier of the organism. It protects from external harm and senses danger signals. It contains a sophisticated immune system that involves armada of immune cells comprising keratinocytes, resident antigen-presenting cell, innate lymphoid cells, innate-like cells, and adaptive tissue-resident memory cells and molecular mediators. The skin hosts also microbial communities recognized as skin microbiota that constitutes one living response barrier to environmental factors. Those microorganisms live in complete harmony with the immune players and are involved in the epithelial barrier reinforcement. Under homeostasis, an established alliance of immunity and microbiota intermingles innate and adaptive branches of the immune system. Under various types of stress, the symbiotic relationship changes into a dysbiotic one resulting in skin disorders. The talk will be focused on the cutaneous immune system from cellular to molecular actors and how skin microbiota can acts to limit pathogenic microbial invasion and to promote various aspects of immune responses.

For media information:
International Society of Microbiota
Media center:
Contact: [email protected]
www.microbiota-site.com

Development and Investment Landscape in the Microbiome

During the congress, Dr. Peter Bak, Back Bay Life Science Advisors, USA will provide his vision and recommendations.

The title of his presentation is 'Corporate Development in the Microbe Space: Has Investment Outpaced Science?'

1) Microbiome Company Landscape
2) Current State of Clinical Development
3) Investment and Corporate Considerations

Prof. Marvin Edeas and his team presented a study on Intelligence Artificial and Health meeting at University Paris-Sud

The Intelligence Artificial and Health meeting was held on November 25, 2019, at University Paris-Sud. During the meeting, Prof. Marvin Edeas from INSERM - U1016, Institut Cochin, Hôpital Cochin, University Paris Descartes with his team presented a study entitled "Artificial Intelligence in the Healthcare Industry: The Hemodialysis patients with cramps initiative".

Introduction
Artificial intelligence in the healthcare industry will open a huge opportunity. Demand for basic and advanced analytics is growing exponentially in healthcare. We are beginning to enter into an era where life sciences and data science are merging. Our initiative will collect clinical data from hemodialysis patients, which will urgently need a Data Scientists to process it. To be able to analyze and make recommendations based on this data, we need AI.

Methods
For the first time we published in 2018 a possible link between Microbiota quality, mitochondrial activity and the occurrence of muscle cramps in hemodialysis patients using citrate dialysate. Our objectives were to assess the gut microbiota quality, mitochondrial activity, and to investigate their possible relationship with HD-associated muscle cramp (HDAMC). This clinical study revealed a possible dysbiosis of microbiota and mitochondrial dysfunction in HD patients with cramps under CD compared to patients without cramp.

Confirmation of our observations is required in a large-scale study, which could demonstrate a novel pathophysiological mechanism linking muscle cramps to gut microbiota HD patients. We now have a cohort of more than 1500 patients to complete our study.

Results Expected
We will use a combined microbiome and metabolome signatures in feces and metabolome in plasma as new biomarkers to identify in upstream the HD patients with altered metabolism in order to propose an adapted therapy. Advances in sequencing technologies could provide opportunities to understand not only the taxonomy but also the functional diversity of gut microbiota. These investigations could allow to justify the use of antibiotics, probiotics, prebiotics, or fecal microbiota transplantation to modulate gut microbiota as curatives or preventive strategies of muscle cramps. We will also look for a predictive marker of muscle cramps by initiating an Artificial Intelligence program.

Conclusion

There are significant hurdles to be overcome with our hemodialysis initiative: 1-finding talented data scientists. 2- regulatory aspects. This presentation will address these considerations.

Durand, P.-Y., Nicco, C., Serteyn, D., Attaf, D. & Edeas, M. Microbiota Quality and Mitochondrial Activity Link with Occurrence of Muscle Cramps in Hemodialysis Patients using Citrate Dialysate: A Pilot Study.

Blood Purif. 46, 301–308 (2018).

For more info, please check the agenda here: http://www.medecine.u-psud.fr/fr/recherche/colloque-intelligence-artificielle-et-sante.html

Prof. Peter Kuntorek and Prof. Marvin Edeas from the International Society of Microbiota will talk during the 9th Latvian Gastroenterology Congress

Prof. Peter Konturek from Teaching Hospital of the University of Jena, Germany will talk about "Fecal microbiota transplantation as a powerful tool for modulating of gut".

Final Agenda & Abstracts Book of Microbiota 2019 Congress

The International Society of Microbiota is pleased to welcome Biocrates Life Sciences AG to the 7th Targeting Microbiota World Congress 2019 !

Biocrates Life Sciences AG, internationally renowned developer of targeted metabolic phenotyping solutions, supports the discovery and validation of biomarkers for complex multifactorial diseases in pre-clinical and clinical research.

Based in Innsbruck and with a subsidiary in the US, the company provides user friendly and ready to measure kits for quantitative, mass spectrometry based metabolite analysis.

Biocrates MxP Quant 500 Kit allows standardized measurement of up to 630 metabolites, many of which are associated with microbial metabolism (such as secondary bile acids).

This enables researchers to unravel the functional relationship between host, nutrition and the microbiome.

DNA Genotek received the ISM Industrial Award during Targeting Microbiota 2019

International Society of Microbiota (ISM) is honored to announce DNA Genotek as one of three winners of the Industrial Innovation Awards, during the 7th World Congress on Targeting Microbiota 2019, which was held in Krakow, Poland.

DNA Genotek is recognized as a leader worldwide in the production and development of standardized skin microbiome and fecal metabolomics collection methodologies.

Testimonial by Heloise Breton, from DNA Genotek:
"We would like to thank the scientific committee for awarding us the the industrial innovation award. As a company dedicated to developing products to optimize ease of collection and provide superior samples and proven performance, we are so happy to see our value in the industry recognized. This year’s Targeting Microbiota conference consisted of many great talks that captured the role of the microbiome in human and animal systems. The connection between the brain and the gut is a huge development and the work happening in this field will be life changing for neurological diseases such as Alzheimer’s. Skin microbiome is an upcoming topic and of high interest for us as we have been working on a collection device for skin sampling which will launch soon. This is a topic that has many applications as seen in the talks regarding cosmetics, immune function and cutaneous homeostasis. There is so much amazing research happening in Europe and we enjoy being a part of such an innovative scientific community. We hope to see the ISM grow every year and to continue to provide a platform for the future of microbiome research."

Media center: 
Internternational Society of Microbiota
Contact: [email protected]
www.microbiota-site.com

Microbiota and Autism: Recent Advances and Perspectives

Dr. Tatjana Mijatovic from R.E.D. Laboratories, Belgium, one of our sponsor, will join the 7th World congress on Targeting Microbiota 2019 Congress and give a key presentation entitled "Biomedical approach in autism spectrum disorders – the importance of assessing inflammation".

International Society of Microbiota awarded R.E.D. Laboratories during Targeting Microbiota 2019

International Society of Microbiota (ISM) is honored to discern Industrial Innovation Award to R.E.D. Laboratories during the 7th World Congress on Targeting Microbiota 2019, which was held in Krakow, Poland.

R.E.D. Laboratories highlighted the high importance of assessing inflammation-related markers in the evaluation of autism spectrum disorders-diagnosed patients.

Testimonial by Dr. Tanja Mijatovic, from R.E.D. Laboratories:
"I really enjoyed the Conference, it was all very well organized and extremely professional.  A great conference to attend for anyone in the microbiome fields. Great for gaining insights into unpublished research and clinical findings, and a significant opportunity to network with enthusiastic colleagues. I came back with valuable insights and fully charged with positive emotions. Huge thanks to the organizers. It was amazing to be awarded. Looking forward to be back next year."

Media center: 
International Society of Microbiota 
Contact: [email protected]
www.microbiota-site.com

Intergenerational Transfer of the Atopic-Disease Potential from the Murine Maternal Gut Microbiota Grafted with Human Faecalibacterium Prausnitzii Pathobionts

Prof. Heenam Stanley Kim from Korea University, Korea will join again the Targeting Microbiota 2019 Congress and present his work "Intergenerational Transfer of the Atopic-Disease Potential from the Murine Maternal Gut Microbiota Grafted with Human Faecalibacterium Prausnitzii Pathobionts" during the congress.

For more information: www.microbiota-site.com

Skin-Bacterial Microbiota Communication: A new element in cutaneous neurogenic inflammation

Dr. Marc G.J. Feuilloley from University of Rouen Normandy, France will talk about "Skin-Bacterial Microbiota Communication: A new elment in cutaneous neurogenic inflammation" during the 7th World Congress on Targeting Microbiota scheduled on October 10-11, 2019 at the Park Inn Hotel - Krakow, Poland. 

Dr. Feuilloley will talk during Session "Skin microbiota 2019: From basics to applied cosmetics and skin care" and among the speakers:

Dialogue between the skin and the microbiota: The immune system is under control
Chantal Pichon, French National Centre for Scientific Research, France

Intergenerational Transfer of the Atopic-Disease Potential from the Murine Maternal Gut Microbiota Grafted with Human Faecalibacterium Prausnitzii Pathobionts
Heenam Stanley Kim, Korea University, Korea

Intestinal barrier, gut microbiota and psoriasis
Mariusz Sikora, Medical University of Warsaw, Poland

For more information: www.microbiota-site.com

Fecal preservation by freeze-drying: applications and perspectives

Dr. Julie Reygner from Université Paris Descartes - Faculté de Pharmacie, France will join in the Congress and will present her work entitled "Fecal preservation by freeze-drying: applications and perspectives" during the congress.

Short summary: Fecal microbiota transplantation (FMT) has now evolved into an efficient therapeutic for the management of recurrent Clostridium difficile infections (rCDIs) with an efficient cure rate reaching 85-95%. We have previously shown that a freeze-dried formulation allowed to conserve FMT preparation over 12 months improving standardization of the stool preparation procedures, process time and thus facilitating patient access to this treatment. The new goal is to improve of the selection of donors, beyond safety of stool samples, in order to develop a rational selection of FMT donor according to the pathology to be treated.

Dr. Reygner is also Best Shor oral presentation award winner of last year and presented short oral presentation "A new freeze-dried formulation to conserve stools over 12 months for fecal transplantation".

This year, Dr. Reygner join participate as Major speaker and will elobrate more about her study on Fecal preservation, ecal transplantation.

For more information: www.microbiota-site.com

Industrial Innovation Award was discerned to Sethic Innovation Lab during Targeting Microbiota 2019

The Industrial Innovation Award was discerned to Sethic Innovation Lab during Targeting Microbiota 2019 Congress.

Scientific Committee awarded Sethic Innovation Lab for their innovating cosmetic ingredient OPTIMEALTH^(R), presented as a potent ingredient to prevents and reduce skin infections, inflammation and related disorders such as atopic dermatitis, rosacea, psoriasis, and acne.

Media center: 
International Society of Microbiota
Contact: [email protected]
www.microbiota-site.com

Microbiota Dysbiosis is Associated with HPV-Induced Cervical Carcinogenesis

Dr. Wojciech Kwaśniewski will present the findings of the present study on "Microbiota Dysbiosis is Associated with HPV-Induced Cervical Carcinogenesis". 

Short summary of the talk: "Over the last decade, it has been indicated that the development and introduction of molecular-based technology has provided novel information regarding the composition of the vaginal‐cervical flora, as well as the abnormal colonization of the genital tract by pathogens. It has been reported that microbe‐induced inflammation can contribute to cervical cancer by stimulating the production of specific cytokines and chemokines, which promote proliferation and/or inhibit apoptosis. Microbiota have been demonstrated to increase, as well as decrease susceptibility to HPV infection. The findings of the present study demonstrated a possible interaction between bacterial flora and HPV infection, as well as an association between this interaction and clinical cervical neoplasia."

For more information: www.microbiota-site.com

Dialogue between the skin and the microbiota: The immune system is under control

Dr. Chantal Pichon from French National Centre for Scientific Research (CNRS ), France will join the Targeting Microbiota 2019 Congress and present her research work on interaction between Skin and Microbiota during the presentation entitled “Dialogue between the skin and the microbiota: The immune system is under control“.

For more information: www.microbiota-site.com

Microbiota and cancer : between Detection and Prognosis

Dr. Romain Villeger from the University of Clermont Auvergne, France will give a presentation entitled "Microbiota and cancer : between Detection and Prognosis" during the 7th World Congress on Targeting Microbiota scheduled on October 10-11, 2019 at the ParkInn Hotel - Krakow, Poland.

The Scientific comittee asked Dr Villeger to comment the recent paper publish in sciencemag.org in July 05, 2019 concerning Microbial stages of colorectal cancer.

For more information: www.microbiota-site.com

Submit your questions before September 15, 2019 and WIN…

Despite the wealth of data typically presented, many questions of the participants remain unanswered, and for many scientists, even those who have been considered as keynote speakers, there is only limited opportunity to interact with colleagues.

To facilitate the scientific discussion and make the conference more interactive, the scientific committee has decided to include a round table discussions that address hot topics, challenges and pressing questions to various areas of Microbiota medicine and research.

All questions will be answered and the most pertinent and critical questions will be awarded with the free registration at the Next Microbiota 2020.

All participants are invited to participate in these discussions by sending their questions and thoughts before the meeting by the September 15, 2019 to microbiota(at)microbiota-site.com

Venue & Hotel Booking

Park Inn Hotel Krakow

Ul. Monte Cassino 2 PL-30337 - Krakow - Poland

Book your room here

Single Room: 115€ by night / Double Room: 125€ by night

Please note that due the limited number of rooms,  we have few negotiated rooms from 9th October to 11 October for 2 nights.

Special Rate for Room Booking at Park Inn by Radisson Krakow

Situated close to the area of tourist attractions, Park Inn By Radisson Krakow features views of Krakow, the Wawel Royal Castle and the Kosciuszko Mound. There is also a brief car trip from the Ogrody Krolewskie na Wawelu and Wawel Cathedral. Targeting Microbiota 2019 Committee offers to the congress attendees a special privileged rate for your booking: Single Room: 115€ by night Double Room: 125€ by night (If you would like to see price for DBL room you have to select 2 person on left side of reservation panel and click search.)   These prices include breakfast buffet, Wi-Fi connection and a free access to their modern fitness area.
Online Hotel Booking Promotional Code: MICROB
Terms & conditions: All room reservations during the Targeting Microbiota 2019 congress - October 10 - 11, 2019 will be made via dedicated booking link. This link will transfer you to Hotel website, where your reservation should be completed by you. You will have to guarantee the reservation by credit card. Credit card will be fully charged 14 days prior to your arrival. After this date no free cancelation will be possible and all reservations will be fully charged – 115 EUR/night (SGL room) or 125 EUR/night (DBL room). Paid reservation will be kept till 7.00 a.m. next hotel day. Room prices are valid from Oct 10, 2019 till Oct 12, 2019.

Psychotropic Drugs and Microbiota - Important and Little Known Interaction

During the 7th World Congress on Targeting Microbiota scheduled on October 10-11, 2019 at the ParkInn Hotel - Krakow, Poland, Dr. Igor Loniewski from Pomeranian Medical University, Poland will give a presentation entitled "Psychotropic Drugs and Microbiota - Important and Little Known Interaction".

Summary of presentation: "Alterations in intestinal microbiota have been associated with the use of antidepressants. Antidepressants differ in mechanisms of their antibacterial activity; for example, they affect cellular respiration, whereby Monoamine Oxidase Inhibitors (MAOIs) can disturb bacterial cell-wall synthesis. Tricyclic antidepressants (TCAs) inhibit DNA gyrase activity and plasmid DNA replication. Selective serotonin reuptake inhibitors (SSRIs) inhibit bacterial efflux pumps. Escitalopram has also antibacterial activity, moreover it was also shown that a six-week escitalopram treatment in a psychiatric hospital setting resulted in increased alpha biodiversity in fecal microbiota Antipsychotic treatment-related microbiome alterations potentially result in body weight gain and metabolic disturbances. Inflammation and resting metabolic rate suppression seem to play crucial roles in the development of metabolic disorders. However in our study we found that the microbiota of schizophrenia patients is highly individual but can be divided into different taxonomical and functional clusters and it does not change following six weeks of olanzapine therapy. Microbiota did not affect either the weight gain observed in women or the effectiveness of olanzapine therapy."